$AFCG

Advanced Flower Capital Inc. (AFCG): Results of Operations and Financial Condition

Advanced Flower Capital Inc. (AFCG) filed an SEC Form 8-K — Results of Operations and Financial Condition. AFC Announces Financial Results for the Second Quarter 2026 Second quarter 2026 GAAP net investment income (“NII”) of $3.5 million, or $0.15 per weighted average share WEST PALM BEACH, FL, August 13, 2026 – Advanced Flower Capital Inc. (Nasdaq: AFCG) (“AFC,” or the “Company”) tod

Original reporting
Published Aug 13, 2026, 11:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AFCG
Bullish
medium confidence
Mentioned
$AFCG
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AFCGBullishMed
01

Why it matters

For AFCG, the key tradable elements are NAV per share progression, GAAP net investment income per share, and the magnitude of buybacks at a stated discount to NAV that generated per-share accretion.

02

Market read

This is a primary earnings-style disclosure for AFCG with multiple fresh balance-sheet and capital-return datapoints that can move discount-to-NAV and income expectations.

03

What to watch

The release emphasizes weighted average yield (13.2%) and portfolio size, but does not provide detailed credit quality metrics or non-accrual trends in the excerpt; those could temper enthusiasm.

Relevance 7/10Novelty 8/10Timing: pre-market/market-open positioning after the Aug 13 8-K earnings release

Background

Advanced Flower Capital Inc. filed an 8-K with Q2 2026 results (Item 2.02) including NAV, income, portfolio composition, liquidity, and its share repurchase program activity.

Company-level read

Ticker impact

$AFCGBullishMedium confidence
Context

AFCG reported Q2 2026 GAAP net investment income of $3.5M, NAV per share rising to $8.25 from $7.90, plus $2.8M buyback accretion.

Expected impact

Moderately positive bias for the next session(s), with traders watching whether NAV growth and buyback accretion persist.

Evidence & confidence

The filing discloses multiple fresh, decision-relevant datapoints: GAAP NII per share ($0.15), NAV per share ($8.25), and repurchase activity (839,406 shares at $3.29) that explicitly generated NAV accretion ($0.17 per share).

Market effects

Adds another datapoint on BDC-style credit income durability and NAV support via buybacks, relevant to peers’ discount-to-NAV narratives.

No clear regional spillover beyond US small-cap/BDC investor sentiment.

Limited global relevance; primarily impacts US listed BDC/credit-income comps.

Counterpoint

NAV per share rose, but total investment income and net unrealized gains can be volatile; traders may discount the quarter if credit performance deteriorates later.

Key entities

  • Advanced Flower Capital Inc.

    Nasdaq-listed business development company reporting Q2 2026 financial results and buyback activity.

  • Dan Neville

    Chief Executive Officer quoted on Q2 NII and NAV accretion from repurchases.

Related articles

$AFCGMed

Advanced Flower Capital (AFCG) Q2 2026 Earnings Call Transcript

Advanced Flower Capital (AFCG) reported Q2 2026 net investment income of $3.5M, or $0.15 per share, with NAV per share rising to $8.25. The company repurchased 839,406 shares and has a $1.3B investment pipeline. Management highlighted rising default rates in private credit and challenges in the cannabis industry. AFCG is resolving nonaccrual loans and focusing on lower middle market borrowers.

$AFCGMed

AFC Commits $7 Million to a Senior Credit Facility

Advanced Flower Capital Inc. (Nasdaq: AFCG) said it committed $7.0 million to a $25.0 million senior secured credit facility, including a term loan and delayed draw term loan. An AFC affiliate will add $5.0 million, for $12.0 million total. Proceeds will refinance existing capital and fund acquisitions for an outpatient behavioral health platform. The facility has a four-year term.

$PAHCMedAI 8/10

Phibro Animal Health (PAHC) Sets 2027 Guidance, Is The Stock Still A Bargain?

Phibro Animal Health (PAHC) issued 2027 guidance, projecting net sales of $1.55b-$1.60b and net income of $122m-$132m. The company reported 2026 sales of $1.518b and net income of $99.72m. Analysts' price targets range from $38 to $58, with a consensus of $45.60, suggesting a 16.1% undervaluation. The stock has seen a 90-day return of 17.95% and a 3-year return above 200%.

$HONMed

Honeywell Is Now Three Companies. Here's Which Piece I'd Actually Own.

Honeywell has split into three companies: Honeywell Technologies (HON), Solstice Advanced Materials (SOLS), and Honeywell Aerospace (HONA). Honeywell Technologies, led by CEO Vimal Kapur, reported strong automation sector growth with 16% order increase and 10% earnings growth. Solstice Advanced Materials showed 11% sales growth and 23% EPS increase, while Honeywell Aerospace lowered guidance.

$PATHMed

Why UiPath Stock Plunged Today

UiPath (NYSE: PATH) shares fell after its Q2 fiscal 2027 earnings, despite revenue growth of 13% to $410M and adjusted operating income up 43% to $89M. CEO Daniel Dines highlighted the company's strategy of using AI where it adds value. Analyst Kingsley Crane downgraded the stock to 'hold', citing competitive threats from AI-powered rivals like Salesforce.